A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Clinical trial NCT07361510 · RECRUITING

Trial details

NCT number: NCT07361510
Sponsor: Bristol-Myers Squibb
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer (NSCLC)

Start date: 2026-03-12
Primary completion: 2031-10-14
Enrollment: 750

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.